The financial burden of morbidity in HIV-infected adults on antiretroviral therapy in Côte d’Ivoire.
Arnousse Beaulière, Siaka Touré, Pierre-Kébreau Alexandre, Koko Koné, Alex Pouhé, Bertin Kouadio, Neige Journy, Jérôme Son, Virginie Ettienne-Traoré, François Dabis, et al.

To cite this version:
Arnousse Beaulière, Siaka Touré, Pierre-Kébreau Alexandre, Koko Koné, Alex Pouhé, et al.. The financial burden of morbidity in HIV-infected adults on antiretroviral therapy in Côte d’Ivoire.. PLoS ONE, Public Library of Science, 2010, 5 (6), pp.e11213. <10.1371/journal.pone.0011213>. <inserm-00521955>
The Financial Burden of Morbidity in HIV-Infected Adults on Antiretroviral Therapy in Côte d’Ivoire

Arnousse Beaulière1,2, Siaka Touré2,4, Pierre-Kébreau Alexandre3, Koko Koné2,5, Alex Pouhé6, Bertin Kouadio2,4, Neïge Jouny1,2, Jérôme Son1,2, Virginie Ettigègne-Traoré6, François Dabis1,2, Serge Eholié2,7, Xavier Anglaret1,2

1 INSERM, Unité 897, Université Victor Segalen Bordeaux 2, Bordeaux, France, 2 Programme PAC-CI, Abidjan, Côte d’Ivoire, 3 Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America, 4 Association ACONDA-VS, Abidjan, Côte d’Ivoire, 5 Institut Pédagogique National de l’Enseignement Technique et Professionnelle (IPNETP), Abidjan, Côte d’Ivoire, 6 Programme National de Prise En Charge des Personnes infectées par le VIH (PNPEC), Ministère de la Santé et de l’Hygéne Publique, Abidjan, Côte d’Ivoire, 7 Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire (CHU) de Treichville, Abidjan, Côte d’Ivoire

Abstract

Background: Large HIV care programs frequently subsidize antiretroviral (ARV) drugs and CD4 tests, but patients must often pay for other health-related drugs and services. We estimated the financial burden of health care for households with HIV-infected adults taking antiretroviral therapy (ART) in Côte d’Ivoire.

Methodology/Principal Findings: We conducted a cross-sectional survey. After obtaining informed consent, we interviewed HIV-infected adults taking ART who had consecutively attended one of 18 HIV care facilities in Abidjan. We collected information on socioeconomic and medical characteristics. The main economic indicators were household capacity-to-pay (overall expenses minus food expenses), and health care expenditures. The primary outcome was the percentage of households confronted with catastrophic health expenditures (health expenditures were defined as catastrophic if they were greater than or equal to 40% of the capacity-to-pay). We recruited 1,190 adults. Median CD4 count was 187/mm³, median time on ART was 14 months, and 72% of subjects were women. Mean household capacity-to-pay was $213.7/month, mean health expenditures were $24.3/month, and 12.3% of households faced catastrophic health expenditures. Of the health expenditures, 75.3% were for the study subject (ARV drugs and CD4 tests, 24.6%; morbidity events diagnosis and treatment, 50.1%; transportation to HIV care centres, 25.3%) and 24.7% were for other household members. When we stratified by most recent CD4 count, morbidity events related expenses were significantly lower when subjects had higher CD4 counts.

Conclusions/Significance: Many households in Côte d’Ivoire face catastrophic health expenditures that are not attributable to ARV drugs or routine follow-up tests. Innovative schemes should be developed to help HIV-infected patients on ART face the cost of morbidity events.

Citation: Beaulière A, Touré S, Alexandre P-K, Koné K, Pouhé A, et al. (2010) The Financial Burden of Morbidity in HIV-Infected Adults on Antiretroviral Therapy in Côte d’Ivoire. PLoS ONE 5(6): e11213. doi:10.1371/journal.pone.0011213

Editor: Pieter H. M. van Baal, Erasmus University Rotterdam, Netherlands

Received December 23, 2009; Accepted May 28, 2010; Published June 18, 2010

Copyright: © 2010 Beaulière et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was funded by the French National Agency for Research on AIDS and viral hepatitis (ANRS 12137, France) (http://www.anrs.fr). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: arnousse.beauliere@isped.u-bordeaux2.fr

Introduction

The World Health Organization (WHO) estimated that 480,000 adults and children were living with HIV in Côte d’Ivoire, West Africa in late 2007. Of the 190,000 persons who were estimated to be in need of antiretroviral therapy (ART), 51,812 (28%) were actually receiving ART [1]. Most of these patients had started ART within the previous three years, primarily thanks to support from the US President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria [2].

In most African countries that receive funds from these international programs, antiretroviral drugs and follow-up tests have become widely available at relatively low costs. In Côte d’Ivoire, HIV-infected patients paid a fixed rate of US$1.5 per month per family from 2005 to 2008, to have access to ARV drugs and CD4 count tests [3]. As of August 2008, ARV drugs and CD4 tests are entirely free for patients. All other health care expenses, including cotrimoxazole prophylaxis, diagnostic tests, and treatment of morbidity events after ART initiation, however, continue to be borne by the patients [1,2]. The HIV virus reduces the concentration of CD4+ T cells in the blood, thus suppressing the immune system and increasing the risk of developing opportunistic diseases. As CD4 counts decrease, the incidence of opportunistic diseases increases. ART curbs viral replication in patients infected with HIV, thereby restoring the immune system, increasing the CD4+ T cell count, and reducing the risk of morbidity.

The financial burden of intercurrent morbidity events for HIV-infected patients must be determined as a function of CD4 count,
because it is likely to decline rapidly after ART initiation and increases in CD4 counts [4–6]. Although it is reasonable to expect that the financial burden of HIV on households decreases considerably after ART initiation, preliminary evidence suggests the contrary [2,4–6]. To explore this issue, the Côte d’Ivoire Ministry of Health has recommended that studies be conducted on health care expenses among HIV-infected patients initiating ART in Côte d’Ivoire.

Here we report the health-related expenditures of adults on ART in Côte d’Ivoire.

Methods

Data collection

We conducted a two-month cross-sectional survey from June to July 2007 in 18 health care facilities, 16 in Abidjan, the economic capital, and two in provincial towns. These public or non-profit private health centres all participate in the Aconda HIV care network. Aconda, a non-governmental organization that is dedicated to HIV/AIDS care and treatment, has been described elsewhere [7]. Study participants were selected sequentially. One patient out of every X patients who presented to care between March 1 and April 30, 2007 was asked to participate. The inclusion rate X differed by study center and was equal to A/(B×70%), where A was the sample size at the study center, B was the anticipated number of patients who would visit the center during the study period, and 70% was the anticipated proportion of patients who would accept to participate. The sample size A at each study center was the overall study sample size multiplied by the number of patients in active follow-up at the study center and divided by the number of patients in active follow-up at all 18 study centers.

Overall, 1,451 adults taking ART who had attended one of the 18 HIV care centres were randomly chosen to participate in a face-to-face interview. 1,275 HIV-infected patients accepted to be interviewed and gave verbal informed consent – informed consent took the form of an open, easily understood communication process between investigator and subject approved by the national ethics committee. After obtaining verbal informed consent, investigators used a standardized questionnaire to record data on household structure, and expenses during the past three months.

When patients did not have some of the requested information, we asked for their permission to contact the head of the household or any other adult household member who could answer our questions. The unit of observation was one patient per household.

Individual data on HIV disease, including most recent CD4 count and history of ART, were gathered from each patient’s personal medical record at the HIV care centre.

This study was approved by the Ethics Committee of the Côte d’Ivoire Ministry of Health and the Institutional Review Board of the French National Agency for AIDS research and viral hepatitis (ANRS).

Variables definition

Total household expenditures were defined as the sum of the expenses of all household members over the past three months. Expenditures were classified as food expenditures, health care expenditures, and other expenditures (electricity, water, telephone, school fees, transportation non-related to health, etc) [8,9].

Household capacity-to-pay was defined as the household’s non-subsistence expenses, i.e. total household expenditures minus food expenditures [10–13].

Health expenditures were stratified into two groups: expenditures related to treatment of the HIV-infected study subject, and expenditures related to the treatment of other members of the family (whose HIV serostatus was unknown). Health expenditures for the HIV-infected study subjects were divided into three groups: (i) ARV drugs and routine follow-up tests, which were available to all HIV-infected patients living in Côte d’Ivoire at a fixed rate of US$ 1.3 per month at the time of the survey; (ii) other medical expenditures (medical consultations, hospital stays, non-CD4 tests, and non-ARV drugs), and (iii) non-medical health-related expenditures (transportation to HIV care centres and housing near health facilities).

Health expenditures are defined as catastrophic when they exceed a given proportion of household resources [13,16]. We used the WHO definition, which characterizes health expenses as catastrophic when they are greater than or equal to 40% of a household’s capacity-to-pay [11].

Statistical analysis

Expenses were estimated in US dollars ($). Each variable was estimated per household. We determined the mean, standard deviation, median, interquartile range, and range of the distribution of each household characteristic in the study population. Data were described both overall, and stratified by most recent CD4 count (<100, 100–199, 200–349, 350–499, and ≥500/mm³). We analysed differences in main outcomes by CD4 category using parametric or non-parametric tests, depending on the distribution of the variable. We determined the factors associated with catastrophic health expenditures using univariate and multivariate logistic regression.

Analyses were performed using STATA 10 software (StataCorp, College Station, Texas, USA).

Results

Socio-demographic and clinical characteristics

Among the 1,275 HIV-infected patients on ART who accepted to be interviewed and gave verbal informed consent, 85 (6.7%) were excluded from the analysis, because their CD4 counts had not been measured in the previous 12 months. Of the remaining 1,190 patients that we included in the analysis, 72% were female and 45% were heads of household. The main clinical and socio-demographic characteristics of these patients are reported in Table 1. Nine percent of households had a health insurance scheme.

Expenditures

Investigators collected information from 1,158 patients (97.3%) on household structure and expenses in order to complete the questionnaire. We interviewed other adult household members to complete the questionnaire for the remaining 32 (2.7%) patients.

Mean overall household expenditures were $313.8 per household per month (Table 2). When we subtracted food from the overall household expenditures, mean household capacity-to-pay was $213.7 per month. Health care expenditures accounted on average for 9.9% of overall household expenditures, and 17.7% of the capacity-to-pay (standard deviation 0.5%, median 10.4%, interquartile range [IQR] 5.2%–21.9%). On average, 75.3% of health expenditures were for the study subjects (ARV drugs and CD4 tests, 24.6%; other tests and drugs, 30.1%; and transportation to HIV care centre, 25.3%), and 24.7% were for other members of the household.

Figure 1 and Figure 2 illustrate the components of household health expenditures, stratified by most recent CD4 count. As shown in Figure 1, overall health expenditures and expenditures related to treatment of the study subject were significantly lower...
when patients had higher CD4 counts (p = 0.03 and p < 0.001, respectively). Health expenditures for other members of the household did not differ significantly by CD4 count (p = 0.77). As shown in Figure 2, spending on ARV drugs and routine tests was slightly lower, and spending on non-ARV drugs and non-CD4 tests was dramatically lower, when patients had higher CD4 counts. Both differences were significant (p < 0.001 and p < 0.001, respectively).

Figure 3 shows the percentage of households whose health expenditures/capacity-to-pay ratios reached various thresholds. Twelve percent of households met the WHO definition for catastrophic health care expenditures (health expenditures greater than or equal to 40% of the household’s capacity-to-pay), 28% of households had ratios above 20%, and 50% of households had ratios above 10.4%.

The following factors were associated with catastrophic health expenditures in multivariate analysis (Table 3): increased time spent on ART (adjusted odds ratio [AOR] 0.97; 95% confidence interval [CI] 0.94–0.99), female HIV-infected patients (AOR 0.58; 95%CI 0.46–1.33), secondary level of education of the household head (AOR 0.31; 95%CI 0.15–0.63), increased household size (AOR 0.73; 95%CI 0.66–0.81); highest household income quartile (AOR 0.27; 95%CI 0.07–1.12). There was no significant association between catastrophic health expenditures and household having a health insurance scheme (AOR 0.59; 95%CI 0.13–2.55).

Differences between patients who were excluded due to missing CD4 counts and patients who were included in the study were significant for mean age (34 vs. 37 years, p = 0.01) and mean health expenditures among HIV-uninfected members of households ($5.8 vs. $10.4/month, p = 0.01). Differences in all other variables, including total household expenditures, total health expenditures and food expenditures, were not significant.

**Discussion**

We investigated the burden of health care expenditures among households with HIV-infected adults on ART in Côte d’Ivoire, West Africa. Our findings add to the literature on the economic impact of chronic diseases such as HIV/AIDS on households in resource-limited settings [6,12–20].

In the early era of large HIV care and treatment programmes in sub-Saharan Africa, the emphasis has been on improving access to

---

**Table 1.** Characteristics of patients and households (N = 1190).

| Patient characteristics | Median (IQR) |
|-------------------------|-------------|
| Most recent CD4 count (cell/mm³), median (IQR) | 187 (88–301) |
| Median time (months) since most recent CD4 count, median (IQR) | 5.5 (3.4–7.5) |
| CD4 stratum (cell/mm³), number (%) | |
| <100 | 330 (27.7) |
| 100–199 | 301 (25.3) |
| 200–349 | 332 (27.9) |
| 350–499 | 124 (10.4) |
| ≥500 | 104 (8.7) |
| Time spent on ART (months), median (IQR) | 14 (7–23) |
| Age (years), median (IQR) | 37 (31–43) |
| Women, number (%) | 857 (72) |
| Employment sector of the patient, number (%) | |
| Formal | 167 (14) |
| Informal | 559 (47) |
| Unemployed | 464 (39) |
| Patient is household head, number (%) | 535 (45) |

**Structure of the households**

| Number of household members, median (IQR) | 5 (3–8) |
| Level of education of the household head, number (%) | |
| None | 500 (42) |
| Primary | 286 (24) |
| Secondary | 309 (26) |
| University | 95 (8) |

---

**Table 2.** Household expenditures.

| | Mean value US$ per month (SD) | Mean percentage |
|-------------------------|-------------------------------|-----------------|
| Total household expenditures* | 313.8 (14.9) | 100% |
| Food expenditures | 100.1 (2.2) | 39.7% |
| Non-food non-health expenditures | 189.4 (14.2) | 50.5% |
| Health expenditures | 24.3 (1.5) | 9.9% |
| For the HIV-infected study subject | 13.8 (0.7) | - 75.3% 100% |
| Antiretroviral drugs and CD4 count tests | 1.9 (0.0) | - - 24.6% |
| Other medical costs** | 8.8 (0.7) | - - 50.1% |
| Transportation | 3.1 (0.2) | - - 25.3% |
| Other members of the household | 10.5 (1.2) | - 24.7% |

---

**Footnotes for table 1:**

%: percentage.

IQR: interquartile range.

ART: antiretroviral therapy.

Most recent CD4 count: all within the past 12 months; median time since the most recent CD4 count was 5.5 months (IQR 3.4; 7.5).

Formal sector: public or private sector employment registered with the income (or profit) tax authorities.

Informal sector: employment in at least one unorganized enterprise in the last 7 days, irrespective of employment status and regardless of whether it was the primary or secondary job.

doi:10.1371/journal.pone.0011213.t001

**Footnotes for table 2:**

ARV: antiretroviral.

Capacity-to-pay: non-subsistence expenses, i.e. total household expenditures minus food expenditures.

*Self-declared expenditures in FCFA converted at exchange rate US$1 = 420 FCFA at time of survey (June–July 2007).

**Other drugs and tests, medical consultations, and hospital stays.

doi:10.1371/journal.pone.0011213.t002
ARV drugs and routine tests. Previous studies have shown that out-of-pocket payments for drugs and tests act as a barrier to care, and that clinical outcomes are worse in settings in which drugs and routine tests are not free [4,21,22,23,24]. These findings have largely contributed to the decision of program funders to make ARV drugs and routine tests available free of charge throughout the continent.

ARV drugs and routine tests were available at a very low cost in Côte d’Ivoire at the time of our study, and have recently become entirely free. Our study suggests that this decision is unlikely to alleviate the economic burden of HIV care on households, because the majority of health expenditures are for non-ARV drugs, non-routine tests, medical consultations and hospital stays. A significant proportion of households with patients on ART, therefore, continue to be confronted with catastrophic health expenditures. Catastrophic health expenditures are defined as health care costs that constitute a large share of household resources and either divert from consumption of basic goods or force the household to use savings, sell assets, or borrow money [10,25]. Our results strongly suggest that morbidity events in patients on ART represent a significant economic burden for households, even when patients have CD4 counts above 200 [26]. In multivariate analysis, the risk of catastrophic household health expenditures decreased with increased time spent on ART, female HIV-infected patients, head of household education level and household size. As expected, households with higher incomes were at lower risk of incurring catastrophic health expenditures than households with lower incomes [14,27]. Several hypotheses may explain our finding that the households of HIV-infected women are less likely to be associated with catastrophic spending. First, female patients may have unequal access to care compared to men. Their health expenditures may therefore be lower than those of male patients. Our finding is more likely due, however, to the fact that women in Côte d’Ivoire are generally not the main income earner of their household. HIV-infected women thus have a smaller impact on their households than HIV-infected men. When the HIV-infected person is the main income earner, time since infection becomes a critical factor in determining whether household expenditures will become catastrophic. If the patient’s disease worsens, health expenditures increase and other household expenditures become more difficult to sustain. We also found that the presence or absence of health insurance had no impact on results, suggesting that having insurance does not protect households from catastrophic spending.

Our study has several limitations. First, we only calculated direct costs. If we had integrated indirect costs, such as time and opportunity costs, we likely would have found that morbidity events in patients on ART with low or intermediate CD4 counts leads to losses in income and productivity [12,17,28]. Income losses reduce household capacity-to-pay, while productivity losses result in a burden for the community. We probably took some income losses into account when we estimated overall household expenses and capacity-to-pay, but our survey did not deal with productivity losses. Therefore, we cannot determine the impact of non-ART and non-routine HIV care on the community.

Second, we estimated the household burden of health expenditures by estimating the proportion of the capacity-to-pay...
that was spent on health care. Capacity-to-pay was estimated from overall household expenditures, not household self-declared income. We used this method, because the sum of self-reported expenditures is considered to be a better approximation of the household’s real purchasing power than the sum of self-reported incomes [9]. However, this method does not consider health expenditures that may have been reimbursed by insurance companies. We may have overestimated the burden of health expenditures among the 9% of households who declared having health insurance [8]. However, households with health insurance are generally wealthier than those without it [29], so it is unlikely that they introduced a major bias in our main results.

This study likely underestimated the economic consequences of HIV care on households, for several reasons. First, we were only able to gather data on one HIV-infected patient per household. In households with more than one HIV-patient, total household health expenditures were probably significantly higher. Second, we excluded 6.7% of patients from the study because they had not performed CD4 count tests. Although total household expenditures and total health expenditures did not differ significantly between excluded patients and included patients, it is still possible that excluded patients were poorer than patients who were included in the study. Third, some authors suggest using shorter recall periods for regular purchases like food, and longer recall periods for durable goods such as rent [15]. Because we asked households to recall all expenditures, including food and housing, in the previous 3 months, we may have underestimated both regular purchases and durable goods. Fourth, 16 of the 18 study centers were in the economic capital of Côte d’Ivoire and probably provide care to the wealthier segments of the country’s population. Catastrophic health expenditures are likely to be even higher in other regions of Côte d’Ivoire. Finally, some households may have been using outside funds to cope with the health expenditures associated with HIV at the time of the survey, as suggested by previous studies [12,18,30]. The use of precautionary savings, depletion of assets, and money borrowed from friends and relatives to pay for both health care and other expenses (e.g. school) may have inflated the capacity-to-pay and reduced the perceived proportion of households with catastrophic health expenditures [12,13,15,30–33].

To our knowledge, no other study in Côte d’Ivoire has estimated the expenditures of households with at least one HIV-infected member. We therefore cannot compare our results to previous studies. Nor can we declare that our sample is representative, because our survey was not conducted at the national level. That said, a 2008 national survey of the standard of living in households across Côte d’Ivoire (National Household Living Standard Survey) found that 47.8% of household expenses were related to food, 5.8% were related to health care and 3.7% were related to education [34]. In our study, the proportion of total household expenditures devoted to food (39.7%) was lower than in the general population, while the proportion of total household expenditures used for health-related needs (9.9%) was much higher than in the general population.

Finally, the time since HIV diagnosis at the time of the survey was unknown. It is likely that as households continue to cope with HIV-related health expenses over time, the financial burden becomes increasingly large.

We used a 40% health expenditures/capacity-to-pay ratio to define catastrophic health expenditures, consistent with the WHO definition [10,14,25]. Other studies have used thresholds of 5% or 20% to define health expenditures as high burdens for the household [12,27,35]. When we varied the threshold from 20% to 60%, the percentage of households facing catastrophic health expenditures was 10–28%. While the 40% ratio is commonly used, there is no definitive threshold for establishing when expenditures become catastrophic [14]. This approximate threshold represents the limit under which households must sacrifice basic needs, sell productive assets, incur debt, or be impoverished, in order to finance health expenditures [12,30,36].

In conclusion, our findings suggest that innovative schemes should be developed to help HIV-infected patients on ART face the cost of morbidity events. The recent decision by the
References

1. WHO (2008) The World Health Report 2008. Primary health care. Now more than ever. Geneva: WHO. Available: http://www.who.int/whr/2008/whorn08_en.pdf. Accessed 19 February 2009.

2. WHO, UNAIDS, Unicef (2009) Toward universal access. Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. Geneva: WHO. Available: http://www.who.int/hiv/pub/puapc_2009_en.pdf. Accessed 5 October 2009.

3. Ministère de la Lutte contre le Sida (2008) Suivi de la déclaration d’engagement sur le VIH/SIDA (UNGASS). Rapport national de la Côte d’Ivoire 2008. Abidjan: Ministère de la Lutte contre le Sida. Available: http://data.unaids.org/pub/Report/2008/cote_divoire_2008_country_progress_report_fr.pdf. Accessed 20 July 2008.

4. Brinkhof MW, Boule A, Weigel R, Messou E, Mathers C, et al. (2009) Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med 6: e1000066.

5. Boyer S, Marcellin F, Ongolo-Zogo P, Abega SC, Nantzoungou R, et al. (2009) Financial barriers to HIV treatment in Yaounde, Cameroon: first results of a national cross-sectional survey. Bull World Health Organ 87: 279–287.

6. Ouwoejoke O, Dike N, Chukwuoka C, Usachukwu B, Oyendam C, et al. (2009) Examining catastrophic costs and benefit incidence of subsidized antiretroviral treatment (ART) programme in south-east Nigeria. Health Policy 90: 223–229.

7. Toure S, Kouadio B, Seyre C, Traore M, D’Aubuis-Dogo N, et al. (2008) Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d’Ivoire: 2-year outcomes and determinants. AIDS 22: 1873–1882.

8. Murray CJ, Evans DB, eds. (2003) Health systems performance assessment: debates, methods and empiricism. Geneva: World Health Organization. 900 p.

9. Deaton A, ed. (1997) The analysis of household surveys: a microeconometric approach to development policy. Baltimore: The Johns Hopkins University Press. 488 p.

10. Xu K, Evans DB, Kawabata K, Zeradmiri R, Klusov J, et al. (2003) Household catastrophic health expenditure: a multicountry analysis. Lancet 362: 111–117.

11. Xu K, Evans DB, Carrin G, Aguilar-Rivera AM (2005) Designing health financing systems to reduce catastrophic health expenditure. Technical briefs for policy-makers no 2. Geneva: World Health Organization. Available: http://www.who.int/health_financing/ph_2.pdf. Accessed 11 May 2009.

12. Russell S (2004) The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. Am J Trop Med Hyg 71: 147–153.

13. Wagstaff A, van Doorslaer E (2003) Catastrophe and impoverishment in paying for health care: with applications to Vietnam 1993-1998. Health Econ 12: 921–934.

14. van Doorslaer E, O’Donnell O, Raman-Elya RP, Somamathan A, Adhikari SK, et al. (2007) Catastrophic payments for health care in Asia. Health Econ 16: 1159–1184.

15. Somkotra T, Lagrada LP (2009) Which households are at risk of catastrophic health spending: experience in Thailand under automated coverage. Health Aff (Millwood) 28: w467–478.

16. Wyszywanski L (1986) Families with catastrophic health care expenditures. Health Serv Res 21: 617–634.

17. Veenstra N, Whiteside A (2005) Economic impact of HIV, Best Pract Res Clini Obstet Gynaecol 19: 197–210.

18. McIntyre D, Thiede M, Dahlgren G, Whitehead M (2006) What are the economic consequences for households of illness and of paying for health care in low- and middle-income country contexts? Soc Sci Med 63: 855–865.

19. Hounton SH, Akonde A, Zannou DM, Bashi J, Meda N, et al. (2008) Costing universal access of highly active antiretroviral therapy in Benin. AIDS Care 20: 582–587.

20. Taverner B, Diep K, Vinard P (2008) The cost of universal free access for treating HIV/AIDS in low-income countries: the case of Senegal. In: Coriat B, ed. The political Economy of HIV/AIDS in Developing Countries: TRIPS, Public Health Systems and Free Access. London: Edward Elgar. pp 275–290.

21. Mielati P, Juillet-Amari A, Prudhomme J, Akribi HA, Coulibaly-Traore D, et al. (2003) Socio-economic and health characteristics of HIV-infected patients seeking care in relation to access to the Drug Access Initiative and to antiretroviral treatment in Cote d’Ivoire. AIDS 17 Suppl 3: S56–S58.

22. Kastenr Zen D, Lagha M, Moatti JP (2005) The evaluation of the HIV/AIDS drug access initiatives in Cote d’Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa. AIDS 17 Suppl 3: S1–S4.

23. Furber AS, Hodgson J, Dixon-MacDonald A, Mukasa DS (2004) Barriers to better care for people with AIDS in developing countries. BMJ 329: 1281–1283.

24. Poue M, Mecah F, van Asten H, van der Ven A, Balsuwen R (2008) Barriers to access to antiretroviral treatment in developing countries: a review. Trop Med Int Health 13: 904–913.

25. Xu K, Evans DB, Kadama P, Ndyonga J, Ogwal PO, et al. (2006) Understanding the impact of eliminating user fees: utilization and catastrophic health expenditures in Uganda. Soc Sci Med 62: 866–876.

26. Nombela N, Kouadio B, Toure S, Seyere C, Fosso YA, et al. (2006) Nonantiretroviral drug consumption by CD4 cell count in HIV-infected adults: a 5-year cohort study in Cote d’Ivoire. J Acquir Immune Defic Syndr 41: 225–231.

27. Su TT, Koyaut B, Fossa S (2006) Catastrophic household expenditure for health care in a low-income society: a study from Nouma District, Burkina Faso. Bull World Health Organ 84: 21–27.

28. Duraisamy P, Ganesh AK, Homan R, Kumaramany N, Castle C, et al. (2006) Costs and financial burden of care and support services to PLHA and households in South India. AIDS Care 18: 121–127.

29. WHO (2009) World Health Statistics. Geneva: World Health Organization. 149 p.

30. Russell S (1996) Ability to pay for health care: concepts and evidence. Health Policy Plan 11: 219–237.

31. Pradhan M, Prescott N (2002) Social risk management options for medical care in Indonesia. Health Econ 11: 431–446.

32. Van Damme W, Meessen B, Por I, Kober K (2003) Catastrophic health expenditure: a multicountry analysis. Lancet 362: 111–117.

33. Van Damme W, Meessen B, Por I, Kober K (2003) Catastrophic health expenditure: implications for the measurement of catastrophic expenditures and poverty. Health Econ 17: 1393–1412.

34. International Monetary Fund (IMF) (2009) Côte d’Ivoire: Poverty Reduction Strategy Paper, Washington: International Monetary Fund. Available: http://www.imf.org/external/np/sec/prres/2009_05_20.pdf. Accessed 20 May 2010.

35. Lu C, Blin B, Murray CJ (2009) Limitations of methods for measuring out-of-pocket and catastrophic private health expenditures. Bull World Health Organ 87: 230–244.

36. Ruel S, Gilson L (2006) Are health services protecting the livelihoods the urban poor in Sri Lanka? Findings from two low-income areas of Colombo. Soc Sci Med 63: 1732–1744.

37. Souteyrand YP, Collard V, Moatti JP, Grubb I, Guerma T (2008) Free care at the point of service delivery: a key component for reaching universal access to HIV/AIDS treatment in developing countries. AIDS 22 Suppl 1: S161–S168.
38. Zachariah R, Van Engelgem I, Massaquoi M, Kocholla L, Manzi M, et al. (2008) Payment for antiretroviral drugs is associated with a higher rate of patients lost to follow-up than those offered free-of-charge therapy in Nairobi, Kenya. Trans R Soc Trop Med Hyg 102: 268–293.

39. Mukherjee JS, Ivers L, Leaul et F, Farmer P, Behfouri H (2006) Antiretroviral therapy in resource-poor settings. Decreasing barriers to access and promoting adherence. J Acquir Immune Defic Syndr 43 Suppl 1: S123–126.

40. Vinaud P, Dhop K, Taverne B (2008) Implementing funding modalities for free access: The case for a “purchasing fund system” to cover medical care. In: Coriat B, ed. The political Economy of HIV/AIDS in Developing Countries TRIPS, Public Health Systems and Free Access. London: Edward Elgar. pp 291–311.

41. Palmer N, Mueller DH, Gilson L, Mills A, Haines A (2004) Health financing to promote access in low income settings-how much do we know? Lancet 364: 1365–1370.

42. James CD, Hanson K, McPake B, Balabanova D, Gwatkin D, et al. (2006) To retain or remove user fees?: reflections on the current debate in low and middle-income countries. Appl Health Econ Health Policy 5: 137–153.

43. Gilson L, Kalyalya D, Kuchler F, Lake S, Oranga H, et al. (2001) Strategies for promoting equity: experience with community financing in three African countries. Health Policy 58: 37–67.

44. Ranson MK (2002) Reduction of catastrophic health care expenditures by a community-based health insurance scheme in Gujarat, India: current experiences and challenges. Bull World Health Organ 80: 613–621.

45. Bennett S (2004) The role of community-based health insurance within the health care financing system: a framework for analysis. Health Policy Plan 19: 147–158.

46. Carrin G, Waeltens MP, Criel B (2005) Community-based health insurance in developing countries: a study of its contribution to the performance of health financing systems. Trop Med Int Health 10: 799–811.

47. Molyneux C, Hutchison B, Chuma J, Gilson I, (2007) The role of community-based organizations in household ability to pay for health care in Kilifi District, Kenya. Health Policy Plan 22: 381–392.

48. Loie A, Xu K (2008) Coping with out-of-pocket health payments: empirical evidence from 15 African countries. Bull World Health Organ 86: 849–856.

49. Carrin G, Mathauer I, Xu K, Evans DB (2008) Universal coverage of health services: tailoring its implementation. Bull World Health Organ 86: 857–863.

50. Lange JM, Schellekens OP, Lindauer M, van der Gaag J (2008) Public-private partnerships and new models of healthcare access. Curr Opin HIV AIDS 3: 509–513.

51. Samb B, Evans T, Dybul M, Atun R, Meatti JP, et al. (2009) An assessment of interactions between global health initiatives and country health systems. Lancet 373: 2137–2169.